Vis børsmeldingen
12(th) Annual RNA Therapeutics Virtual Conference, a UK based online event
taking place February 10-11, 2021. The 2021 conference is set to explore the
latest developments in RNA delivery agents and RNA-based therapeutics with the
latest case studies on advanced mRNA technologies, oligonucleotide delivery,
therapeutic applications and future trends and innovations. PCI Biotech is also
a sponsor of the event.
On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will
present an overview of PCI Biotech’s proprietary platform technology, focusing
on the delivery of RNA molecules, including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies.
The presentation slides will be made available through a separate press release
around the timing of the presentation and the full presentation will be made
available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific
publications & presentations” after the event.
Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Kilde
